EXEL Exelixis Inc
Company Analysis
Latest News
Exelixis Hits 52-Week High, Fueled by Oncology Pipeline Optimism
Exelixis Inc. (EXEL) reached a new 52-week high on July 8, 2026. This milestone signals strong upward momentum for the biotechnology firm. Positive analyst...
Exelixis Confronts Mixed Zanzalintinib Data, Following Russell Index Removal
Exelixis faces heightened investor scrutiny following mixed subgroup data from its STELLAR-303 trial for zanzalintinib. This trial targeted metastatic...
🟢 EXEL is trading 5.2% up in pre-market with no clear catalyst yet
EXEL is trading at 5.2% up now at $56.78 in pre-market, a strong move versus its recent tight trading range. So far, there are no fresh earnings, FDA, M&A, or...
Exelixis Shares Fall, as Key Cancer Trial Misses Statistical Significance
Exelixis reported mixed results from its Phase 3 STELLAR-303 trial for the cancer drug zanzalintinib. The trial evaluated the drug in combination with...
🟢 Exelixis Inc is trading 4.9% up today amid positive risk sentiment and broader market strength
Exelixis Inc is trading at $55.00 (4.9% up) in pre-market, extending its recent upward drift after closing at $52.44 on June 17, 2026. • Broader U.S. equity...